Trials / Unknown
UnknownNCT01715532
Role of Huachansu in Treating Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
Phase II Study of Huachansu for Treatment of Advanced Hepatocellular Carcinoma and the Correlation With Na+/K+-ATPase
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Primary Outcome Measures: \- To compare the progression free survival(PFS) in patients with unresectable hepatocellular carcinoma(HCC) treated with transcatheter arterial chemoembolization(TACE) with or without Huachansu, and the correlation between PFS and expression of peripheral Na+/K+-ATPase α3 family. Secondary Outcome Measures: \- To compare the overall survival(OS), objective response rate(ORR), and side effects of treating HCC with TACE plus Huachansu or TACE alone. Exploratory Outcome Measures: \- To evaluate the correlation between prognosis and expression of peripheral Na+/K+-ATPase α3 family.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Huachansu | |
| OTHER | TACE |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2012-10-29
- Last updated
- 2015-12-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT01715532. Inclusion in this directory is not an endorsement.